News | September 07, 2021
Indian Pharmaceutical Market grew by 17.7 per cent in August
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
As of FY21, it is the largest independent medical device company and the second-largest company overall, in the surgical consumables market in India with a 7.91 per cent share based on the value
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
The company has been sold to Shinshin Pharmaceuticals
The Stasis connected care monitoring system includes - a bedside monitor that monitors 6 vital signs, a tablet that enables intuitive monitoring, and the Stasis app that allows for remote monitoring across devices
_256_384.jpg)
As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
Subscribe To Our Newsletter & Stay Updated
